Oramed Pharmaceuticals (Seite 1468)

[kwhistler]

DEN SIE WISSEN WAS SIE TUN!!!

[reaaalist]

Antwort auf Beitrag Nr.: 45.515.425 von kwhistler am 25.09.13 17:05:05

Hey kwhistler,

war gerade bei Ariva!
Wow, da geht aber die Post ab
Die User dort sind ja voll begeistert von Oramed.

Gruß r

[reaaalist]

Antwort auf Beitrag Nr.: 45.515.425 von kwhistler am 25.09.13 17:05:05

Moin kwhistler,

da haben wir gleichzeitig recherchiert!

Ja gut, doppelt hält besser

Gruß r

[reaaalist]

Moin Oramed-Aktionäre und zukünftige Oramed-Aktionäre

hier eine Pressemitteilung:

Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013

http://www.reuters.com/article/2013/09/25/bc-oramed-pharmace…

eine schöne Veranstaltung um weitere Investoren zu generieren!

Gruß r

[kwhistler]

[kwhistler]

...sorry den link vergessen!!


http://markets.on.nytimes.com/research/stocks/news/press_rel…

[kwhistler]

...bald geht's los!!!



Oramed to Participate in Barclays' Israel Biotech Corporate Day in Zurich on September 30, 2013
Published: September 25, 2013
JERUSALEM, September 25, 2013 /PRNewswire/ --

Oramed Pharmaceuticals Inc. (NASDAQCM: ORMP) (http://www.oramed.com), a developer of oral drug delivery systems, announced today that it has been invited to participate in an exclusive Israeli Biotech Corporate Day, hosted by Barclays on September 30, 2013 in Zurich, Switzerland. The event is designed to connect prominent Israeli biotech companies with Barclays' investors for future potential collaborations.

"We are pleased to be invited to this unique event and look forward to connecting with the European investment community," stated Oramed CEO Nadav Kidron.

About Oramed Pharmaceuticals

Oramed Pharmaceuticals is a technology pioneer in the field of oral delivery solutions for drugs and vaccines currently delivered via injection. Established in 2006, Oramed's technology is based on over 30 years of research by top research scientists at Jerusalem's Hadassah Medical Center. Oramed is seeking to revolutionize the treatment of diabetes through its proprietary flagship product, an orally ingestible insulin capsule (ORMD-0801) currently initiating Phase 2 clinical trials on patients with type 2 diabetes (T2DM) under an Investigational New Drug application with the U.S. Food and Drug Administration, and with its oral exenatide capsule (ORMD-0901; a GLP-1 analog), with trials on healthy volunteers (Phase 1b) and T2DM patients (Phase 2a) underway. Oramed is also moving forward with clinical trials of ORMD-0801 for the treatment of type 1 diabetes. The company's corporate and R&D headquarters are based in Jerusalem.

For more information, the content of which is not part of this press release, please visit http://www.oramed.com.

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our clinical trials or when we discuss revolutionizing the treatment of diabetes with our products. These forward-looking statements and their implications are based on the current expectations of the management of Oramed only, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other pharmaceutical or biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; laboratory results that do not translate to equally good results in real settings; our patents may not be sufficient; and final that products may harm recipients, all of which could cause the actual results or performance of Oramed to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Oramed undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Oramed, reference is made to Oramed's reports filed from time to time with the Securities and Exchange Commission.

Company Contact:
Oramed Pharmaceuticals
Aviva Sherman
Office: [phone]
Mobile: [phone]
Email: [e-mail]

SOURCE Oramed Pharmaceuticals Inc.

[reaaalist]

Antwort auf Beitrag Nr.: 45.510.531 von kwhistler am 24.09.13 21:55:46

ah, daher dieses hohe Volumen zum Ende hin

Gruß r

[kwhistler]

so bin auch wieder dabei!!!



;-)

[reaaalist]

Antwort auf Beitrag Nr.: 45.510.363 von kwhistler am 24.09.13 21:30:22

Moin kwhistler,

wo steht denn dat Körbchen?
rechnest du noch mit der 5 vor dem Komma?
Ich glaube, dann werde ich auch noch mal schwach......

Gruß r

PS. hier im Thread ist übrigens Däumchen-pflicht